Stocks Health care AYTU
NASDAQ · Health careAytu Biopharma, Inc (AYTU)
Aytu Biopharma, Inc reported revenue of $57.6M in fiscal 2026, down 13.3% from a year earlier. It posted a net loss of $14.3M. Operating cash flow minus capital spending left $3.3M of free cash flow in fiscal 2026. At June 30, 2026 it held $26.3M in cash against $11M of debt. Its latest periodic report to the SEC is the annual report (10-K) filed on September 22, 2026.
Watch AYTU in 60 secondsWhat Aytu Biopharma, Inc does
Aytu Biopharma, Inc is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker AYTU.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2026 | $57.6M | -$14.3M | -$1.16 | $3.3M |
| 2025 | $66.4M | -$13.6M | -$2.16 | -$2.2M |
| 2024 | $65.2M | -$15.8M | -$2.86 | -$1.7M |
| 2023 | $107.4M | -$17.1M | -$5.11 | n/a |
| 2022 | $96.7M | -$108.8M | -$74.01 | -$28.8M |
| 2021 | $65.6M | -$58.3M | -$68.68 | -$28.3M |
Full financial statements: income, balance sheet and cash flow
Where AYTU ranks in Health care
Latest SEC filings
What Aytu Biopharma, Inc has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 22, 2026Annual report 10-K · period to June 30, 2026Revenue fell 13% to $57.6M versus the prior year; diluted EPS -$1.16 versus -$2.16.
- September 22, 2026
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- June 25, 2026
- May 13, 2026Quarterly report 10-Q · period to March 31, 2026Revenue fell 33% to $12.4M versus the same quarter last year; diluted EPS -$0.53 versus $0.21.
- May 13, 2026
- April 2, 2026
- February 17, 2026Passive stake changed SCHEDULE 13G/A
- February 13, 2026Passive stake changed SCHEDULE 13G/A
- February 3, 2026Quarterly report 10-Q · period to December 31, 2025Revenue fell 6.5% to $15.2M versus the same quarter last year; diluted EPS -$1.05 versus -$0.26.
What is AYTU worth? A DCF from its reported cash flow
Insider trades
What the people running Aytu Biopharma, Inc did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider bought or sold shares on the open market in the last 90 days. The 8 reported changes were pay in shares, option exercises, shares withheld for tax or gifts.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| July 28, 2026 | Donofrio John Jr.Director | Received as pay | 10,000 | - |
| July 28, 2026 | Dockery CarlDirector | Received as pay | 10,000 | - |
| July 28, 2026 | Jain AbhinavDirector | Received as pay | 10,000 | - |
| July 28, 2026 | Liu Vivian HDirector | Received as pay | 10,000 | - |
| July 28, 2026 | Selhorn Ryan JChief Financial Officer | Received as pay | 25,000 | - |
| July 28, 2026 | Disbrow JarrettChief Business Officer | Received as pay | 15,000 | - |
| July 28, 2026 | Pyszczymuka GregChief Commercial Officer | Received as pay | 20,000 | - |
| July 28, 2026 | Disbrow Joshua R.Chief Executive Officer, Director | Received as pay | 30,000 | - |
Who owns AYTU
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Nantahala Capital Management, LLC13D, may seek influence with 2 related filers | 14.4% | June 9, 2025 |
| Stonepine Capital Management, LLC13G, passive with 3 related filers | 9.9% | August 13, 2025 |
| AWM Investment Company, Inc.13G, passive | 5.8% | February 13, 2026 |
Largest institutional holders
Insiders
8 insiders reported holding 558,855 shares in total, about $1.3M at the last price.
| Holder | Shares |
|---|---|
| Disbrow Joshua R.Chief Executive Officer, Director | 237,203 |
| Disbrow JarrettChief Business Officer | 76,568 |
| Selhorn Ryan JChief Financial Officer | 74,743 |
| Pyszczymuka GregChief Commercial Officer | 56,102 |
| Dockery CarlDirector | 31,152 |
| Liu Vivian HDirector | 29,825 |
| Jain AbhinavDirector | 29,500 |
| Donofrio John Jr.Director | 23,762 |
Questions about AYTU
What does Aytu Biopharma, Inc do?
Aytu Biopharma, Inc is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker AYTU.
Is Aytu Biopharma, Inc profitable?
No. In fiscal 2026 it reported a net loss of $14.3M on revenue of $57.6M.
How much revenue does Aytu Biopharma, Inc make?
In fiscal 2026 Aytu Biopharma, Inc reported revenue of $57.6M. That is 13.3% less than a year earlier.
When did Aytu Biopharma, Inc last report?
Its most recent periodic report is the annual report (10-K) filed on September 22, 2026. It covers the period to June 30, 2026.
Similar companies
Compare AYTU with
Follow AYTU
Get an email when Aytu Biopharma, Inc files with the SEC: results, executive changes, material agreements and annual reports.
Follow AYTU: get an email when it filesWhere the numbers come from
Financial figures are the values Aytu Biopharma, Inc tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.